Performance of P2x7 and P2Y Purinergic Receptors as an Inhibiting Factor in the Progression of Pulmonary Neoplastic Cells

Main Article Content

Matheus Ribeiro Bizuti
Laura Nyland Jostl
Emanuely Scramim
Keroli Eloiza Tessaro da Silva
Luana Paula Schio
Gabriela Vidotto Cavallieri
Renata Calciolari Rossi
Débora Tavares de Resende e Silva


Different pathological processes are considered in lung cancer, such as nicotine deposition, oxidative stress, deregulation of metal ions and chronic inflammation. Purine signaling is involved in all processes, suggesting the importance of nucleotide receptors (P2X7 and P2Y) and adenosine receptors present in lung cells. The accumulation of toxic substances promotes chronic inflammation and cellular alteration, which induces the release of Adenosine Triphosphate (ATP) in the extracellular space, thus stimulating P2X7 receptors. The activation of P2X7 promotes an increase in the synthesis and release of some pro-inflammatory mediators. P2Y works by promoting the increase of intracellular calcium levels and, P2X7, changing cell permeability. Thus, drugs can be developed with a specific targeting for such recipients, thus provid additional therapeutic options to those existing.

Adenosine triphosphate, cell proliferation, lung neoplasms, tobacco use disorder, purinergic signaling

Article Details

How to Cite
Bizuti, M. R., Nyland Jostl, L., Scramim, E., Tessaro da Silva, K. E., Schio, L. P., Cavallieri, G. V., Rossi, R. C., & Resende e Silva, D. T. de. (2020). Performance of P2x7 and P2Y Purinergic Receptors as an Inhibiting Factor in the Progression of Pulmonary Neoplastic Cells. Annual Research & Review in Biology, 35(12), 56-62.
Minireview Article


Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.

Kim CH, Lee YC, Hung RJ, Mc Nallan SR, Cote ML, Lim WY et al. Exposure to secondhand tobacco smoke and lung cancer by histological type: A pooled analysis of the International Lung Cancer Consortium (ILCCO). Int J Cancer. 2014; 135:1918-30.

Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175-83.

Ma J, Li W, Chai Q, Tan X, Zhang K. Correlation of P2RX7 gene rs1718125 polymorphism with postoperative fentanyl analgesia in patients with lung cancer. Medicine (Baltimore). 2019;98:e14445.

Miras-Portugal MT, Queipo MJ, Gil-Redondo JC, Ortega F, Gómez-Villafuertes R, Gualix J et al. P2 receptor interaction and signalling cascades in neuroprotection. Brain Res Bull. 2018;151: 74-83.

Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets. 2010;11:1551-70.

Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ et al. CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res. 2010; 70:2245-55.

Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013;9:491-540.

North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013-67.

Turner CM, Elliott JI, Tam FW. P2 receptors in renal pathophysiology. Purinergic Signal. 2009;5:513-20.

Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci. 2007;64:1471-83.

Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35:75-91.

Kanwal M, Ding XJ, Cao Y. Familial risk for lung cancer. Oncol Lett. 2017;13:535-42.

Stefanescu SV, Buciu A, Al-Saffar H, Cirin AB. Dental perspective on radioactive nuclides in humans living on the premises of uranium mining facilities. J Dent Maxillofacial Res. 2020;3:1-5.

Koeller DR, Chen R, Oxnard GR. Hereditary lung cancer risk: Recent discoveries and implications for genetic counseling and testing. Current Genetic Medicine Reports. 2018;6:83-88.

Denton E, Conron M. Improving outcomes in lung cancer: The value of the multidisciplinary health care team. J Multidiscip Healthc. 2016;9:137-44.

Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 2016; 5:288-300.

Zheng M. Classification and pathology of lung cancer. Surg Oncol Clin. 2019;8:447-468.

Wang X, Li L, Guan R, Zhu D, Song N, Shen L. Emodin inhibits ATP-induced proliferation and migration by suppressing P2Y receptors in human lung adenocarcinoma cells. Cell Physiol Biochem. 2017;44:1337-51.

Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, Falzoni S et al. ATP in the tumour microenvironment drives expression of nfP2X. Oncogene. 2019;38: 194-208.

Martínez VR, Aguirre MV, Todaro JS, Piro OE, Echeverría GA, Naso LG et al. Interaction of Zn with losartan. Activation of intrinsic apoptotic signaling pathway in lung cancer cells and effects on alkaline and acid phosphatases. Biol Trace Elem Res. 2018;186:413-29.

Yu C, Jiao Y, Xue J, Zhang Q, Yang H, Xing L et al. Metformin sensitizes non-small cell lung cancer cells to an epigallocatechin-3-gallate (EGCG) treatment by suppressing the Nrf2/HO-1 signaling pathway. Int J Biol Sci. 2017; 13:1560-9.

Lin CC, Lu CH, Pan YH, Jiao L, Chen HY, Li L et al. Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib. Zhonghua Zhong Liu Za Zhi. 2017;39:650-6.

Campos-Contreras AR, Díaz-Muñoz M, Vázquez-Cuevas FG. Purinergic signaling in the hallmarks of cancer. Cells. 2020;9:1-24.

Song S, Jacobson KN, McDermott KM, Reddy SP, Cress AE, Tang H et al. ATP promotes cell survival via regulation of cytosolic [Ca2+] and Bcl-2/Bax ratio in lung cancer cells. Cell Physiology. 2016;310:99-114.

Lara R, Adinolf E, Harwood CA, Philpott M, Barden JA, Di Virgilio F et al. P2X7 in cancer: From molecular mechanisms to therapeutics. Front Pharmacol. 2020;11: 793.